Author name: effrx-wp-admin-2023

EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Lupin for Commercialization of BINOSTO® in Vietnam & Philippines

Freienbach, February 6, 2024 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced that it has signed an exclusive licensing and distribution agreement for Binosto® in Vietnam and the Philippines with Lupin Limited (Lupin), a leading global pharmaceutical company. BINOSTO® (buffered soluble alendronate) […]

EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Lupin for Commercialization of BINOSTO® in Vietnam & Philippines Read More »

EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States

Freienbach, September 19th, 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced that it has signed an exclusive licensing and distribution agreement with Radius Health, Inc for Binosto® for the United States. BINOSTO® is indicated for the treatment of osteoporosis in postmenopausal

EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States Read More »

EffRx Attends the WCO IOF-ESCEO Congress

EffRx Pharmaceuticals is attending the WCO IOF-ESCEO – World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases – which will take place from May 4 -7, 2023 in Barcelona, Spain. The IOF Congress is one of the most significant events in the field of osteoporosis and bone health, bringing together renowned scientists, healthcare professionals, and industry

EffRx Attends the WCO IOF-ESCEO Congress Read More »

EffRx Supports the 16th Annual Rare Disease Day on 28. February 2023

The 16th international Rare Disease Day is on the 28th of February, 2023. Rare Disease Day is the official international awareness-raising campaign for rare diseases. Rare Disease Day takes place on the last day of February each year. The main objective of the campaign is to raise awareness amongst the general public and decision-makers about

EffRx Supports the 16th Annual Rare Disease Day on 28. February 2023 Read More »

EffRx Attending the Annual Meeting SSEDP / SGPED on 26. January 2023 at the Universitäts-Kinderspital Zürich

The Swiss Society for Pediatric Endocrinology and Diabetology (SGPED) is composed of pediatric endocrinologists and individuals from allied health professions. Together with supporting sponsors like EffRx, the Society is jointly committed to improving the care of children and adolescents with endocrinological diseases and diabetes mellitus. For the second year in a row, EffRx will be

EffRx Attending the Annual Meeting SSEDP / SGPED on 26. January 2023 at the Universitäts-Kinderspital Zürich Read More »

EffRx Attends the 1st Eastern Switzerland Symposium on Rare Diseases in St. Gallen, Switzerland

The Eastern Switzerland Symposium on Rare Diseases took place for the first time on November 24, 2022, and attracted a high number of participants from a broad range of disciplines. The motto of the conference, chaired by experts from the Cantonal Hospital St. Gallen and Eastern Switzerland Children’s Hospital, was “Learning from the Rare Diseases

EffRx Attends the 1st Eastern Switzerland Symposium on Rare Diseases in St. Gallen, Switzerland Read More »

EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announces the launch of Alkindi® (hydrocortisone capsules for oral use) in Switzerland as replacement therapy for adrenal insufficiency in infants, children and adolescents (from birth to <18 years old). Alkindi® is the first approved pediatric-specific

EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland Read More »

World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe

World Orphan Drug Alliance (WODA) is a new global alliance of full-service regional distributors for orphan drugs. WODA covers 68 countries on 4 continents. There are more than 64 million potential patients with rare diseases in the WODA regions. Zurich, Ljubljana, Moscow, Sao Paulo, Dubai, May 12, 2022 – EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC, and

World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe Read More »

EffRx Attending the 9th I-DSD Symposium 2022 in Bern, Switzerland, University Hospital Bern from 14-16th July 2022

The International Symposium on the Differences & Disorders of Sex Development I-DSD has been very successful in attracting a rapidly expanding multidisciplinary group of experts, eager to discuss the latest advances in the field and have laid the foundation for fruitful international collaborations. In 2021, the I-DSD/I-CAH/I-TS has a network that reaches 260 centers in 63

EffRx Attending the 9th I-DSD Symposium 2022 in Bern, Switzerland, University Hospital Bern from 14-16th July 2022 Read More »

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland

FREIENBACH, Switzerland –-BUSINESS WIRE–-  EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody® as a treatment for congenital adrenal hyperplasia (CAH) in Switzerland. Under the terms

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland Read More »

EffRx Supports the 15th Annual Rare Disease Day on 28. February 2022

Rare Disease Day is the globally-coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. Since its creation in 2008, Rare Disease Day has played a critical part in building an international rare disease community that is multi-disease, global, and

EffRx Supports the 15th Annual Rare Disease Day on 28. February 2022 Read More »

EffRx Attending the Annual Meeting SSEDP / SGPED on 20. January 2022 in St. Gallen

The Swiss Society for Pediatric Endocrinology and Diabetology (SGPED) is composed of pediatric endocrinologists and individuals from allied health professions. EffRx, a sponsor of SGPED, is jointly committed to improving the care of children and adolescents with endocrinological diseases and diabetes mellitus.

EffRx Attending the Annual Meeting SSEDP / SGPED on 20. January 2022 in St. Gallen Read More »

EffRx Obtains Swiss Marketing Authorization for Alkindi® for Paediatric Adrenocortical Insufficiency

FREIENBACH, Switzerland –-BUSINESSWIRE— EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Alkindi® for the treatment of paediatric adrenocortical insufficiency (AI). Alkindi®, developed by Diurnal Group plc, is the first preparation of hydrocortisone specifically designed for use in children suffering from paediatric adrenocortical

EffRx Obtains Swiss Marketing Authorization for Alkindi® for Paediatric Adrenocortical Insufficiency Read More »

EffRx Obtains Swiss Marketing Authorization for Bronchitol® in Cystic Fibrosis

FREIENBACH, Switzerland –(BUSINESS WIRE)–EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Bronchitol® (inhaled mannitol) for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as add‐on to other medicines. Bronchitol® is a precision spray‐dried

EffRx Obtains Swiss Marketing Authorization for Bronchitol® in Cystic Fibrosis Read More »

EffRx Announces the Appointment of Göran Linder to of the Board of Directors

Freienbach, July 21, 2021 — EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications, today announced the appointment of Göran Linder to its Board of Directors. “As the representative of EffRx’s major shareholder, I actively promoted the turn-around that the company and

EffRx Announces the Appointment of Göran Linder to of the Board of Directors Read More »

A Prospective Study in More Than 1,000 Osteoporosis Patients Concluded That Binosto® (Buffered Soluble Alendronate) May Increase Patient Satisfaction, Long-Term Adherence and Therefore Efficacy

FREIENBACH, Switzerland–(BUSINESS WIRE)– Corporate IR Press Release In a newly published international multicenter study1 in over 1,000 osteoporosis patients treated with Binosto® and followed for 12 ± 3 months, Binosto was well tolerated Treatment persistence was high Mean overall compliance was high too Patient satisfaction remained at approximately 90% EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical

A Prospective Study in More Than 1,000 Osteoporosis Patients Concluded That Binosto® (Buffered Soluble Alendronate) May Increase Patient Satisfaction, Long-Term Adherence and Therefore Efficacy Read More »

EffRx Seeks New Business Collaborations at the BIO International Convention Digital 2021

At the BIO International Convention Digital, taking place June 10-11 & 14-18, 2021, EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases. Registered companies can still meet with EffRx in virtual BIO One-On-One Partnering meetings. Please contact us via the partnering platform or at info@effrx.com. BIO is

EffRx Seeks New Business Collaborations at the BIO International Convention Digital 2021 Read More »

Dr. Nathalie Véron Appointed Director Technical Operations & Qualified Person at EffRx Pharmaceuticals

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA is pleased to announce the appointment of Dr. Nathalie Véron as Director Technical Operations & Qualified Person. She is responsible for overseeing all technical operations activities at EffRx, such as manufacturing relations, supply chain and quality management. Prior to joining EffRx, Dr. Véron has held various local and global,

Dr. Nathalie Véron Appointed Director Technical Operations & Qualified Person at EffRx Pharmaceuticals Read More »

EffRx Pharmaceuticals Announces the Release of Binosto® Data in Two Publications

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced the publication of new scientific data on its Binosto® (buffered soluble alendronate). The data appeared in two major medical journals.1,2 The findings from the study “A novel effervescent formulation of oral weekly alendronate (70

EffRx Pharmaceuticals Announces the Release of Binosto® Data in Two Publications Read More »

EffRx Pharmaceuticals Signs Exclusive License Agreement with Dipharma SA and Launches Miglustat Dipharma in Switzerland

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Dipharma SA, a Swiss specialty pharmaceutical company, developing high quality, improved medicines for rare diseases. Under the terms of the agreement, EffRx has received

EffRx Pharmaceuticals Signs Exclusive License Agreement with Dipharma SA and Launches Miglustat Dipharma in Switzerland Read More »

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi® and Submits Market Authorization Application in Switzerland

FREIENBACH, Switzerland (BUSINESS WIRE)-– EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, for the registration and commercialization of Alkindi® for pediatric adrenocortical

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi® and Submits Market Authorization Application in Switzerland Read More »

wod-banner

EffRx Mourns Passing of Board Member Anders Wiklund

FREIENBACH, Switzerland, 19th August 2020. The leadership of EffRx Pharmaceuticals SA is extremely saddened to announce the passing of longtime Board Member and former Chairman, Anders P. Wiklund. Anders, a Swedish citizen, has been a board member of EffRx since its incorporation in Switzerland in 2009, and served as Chairman of EffRx between 2015 and

EffRx Mourns Passing of Board Member Anders Wiklund Read More »

World Osteoporosis Day – WOD marked on October 20th: THAT’S OSTEOPOROSIS

Countdown to World Osteoporosis Day: A digital countdown checklist is an easy way to learn good bone health basics. Get Started Now! WOD, marked on October 20 each year, is a year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. It aims to put bone

World Osteoporosis Day – WOD marked on October 20th: THAT’S OSTEOPOROSIS Read More »

EffRx to Showcase Binosto® at the Virtual WCO-IOF-ESCEO 2020 Congress

EffRx Pharmaceuticals SA is proud to announce that it will participate in the 20th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, starting on the 20th of August 2020. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to

EffRx to Showcase Binosto® at the Virtual WCO-IOF-ESCEO 2020 Congress Read More »

EffRx Pharmaceuticals Statement on COVID-19

The globe has literally gone into quarantine due to the COVID-19 outbreak. This is an unprecedented crisis situation in terms of breadth and scale, from a global health, social and economic standpoint. While committed to keep our core activities unaffected, EffRx has implemented measures aimed at guaranteeing business operation continuity, with particular focus on the

EffRx Pharmaceuticals Statement on COVID-19 Read More »

Scroll to Top